# Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS)

> **NCT00330681** · PHASE3 · COMPLETED · sponsor: **Tanabe Pharma Corporation** · enrollment: 206 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis (ALS)

## Interventions

- **DRUG:** MCI-186
- **DRUG:** Placebo of MCI-186

## Key facts

- **NCT ID:** NCT00330681
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 206 (ACTUAL)
- **Last updated:** 2026-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00330681

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00330681, "Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00330681. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*